Stavanger UncomPlicatEd Elective PCI Same DaY Discharge Study (SPEEDY Study) (SPEEDY)

April 29, 2019 updated by: Helse Stavanger HF
The purpose of this study is to provide information on safety of same day discharge after uncomplicated percutaneous intervention (PCI) for stable angina pectoris in Norwegian clinical practice. The investigators also think that is in patients interest to stay as short time as possible in hospital and this will be measured using standardised quality of life questionnaires.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The international literature has already provided documentation on the safety of same day discharge in various clinical scenario. In this particular study, the investigators focus on challenging the contemporary Norwegian practice where every body stays over night.

Only patients with stable angina pectoris will be included in the study. After informed consent and successful procedure, the patients will be randomised to same day discharge or standard care. Same day discharge patients will be contacted by telephone the day after the procedure for follow-up conversation with particular emphasis on access site complications.

Both groups will receive quality of life questionnaire within a month for assessment of difference between the two strategies.

Study Type

Interventional

Enrollment (Actual)

82

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Norway
    • Rogaland
      • Stavanger, Rogaland, Norway, 4056
        • Stavanger University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Elective procedures Monday through Thursday
  • Patient consenting for same day discharge
  • Operator has assessed the patient and is in agreement
  • Adequate observational facility
  • Uncomplicated procedure
  • Acceptable social network at home
  • Uneventful post PCI ECG
  • Adequate hemostasis of puncture site

Exclusion Criteria:

  • Angiographic

    • No-reflow/slow flow post PCI
    • Sub-optimal PCI result
    • Dissection type C-E
    • Rest dissection after stent deployment
    • Angiographic thrombus
    • Guidewire perforation

  • Clinical

    • Advanced age
    • Severe renal failure (GFR < 30ml/min)
    • Excessive bleeding risk
    • Symptomatic heart failure
    • Severe visual or hearing impairment
    • Multi-vessel PCI (2 main vessels or left main)
    • Use of GP IIb/IIIa inhibitors

  • Social

    • Living alone or has no telephone
    • Long driving distance (> 30-45 min)
    • Patient/next to keen can´t communicate with health personnel without a translator

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: same day discharge
patients discharged same day after uncomplicated PCI
Procedure: same day discharge
same day discharge after PCI for stable CAD
No Intervention: standard care
standard care where patients are discharged the day after procedure after adequate observation

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
number of complications (access site bleeding)
Time Frame: 1 month
observation of complications requiring intervention
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Helse Stavanger HF

Investigators

  • Principal Investigator: Nigussie Bogale, M.D, PhD, Helse Stavanger HF

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 1, 2015

Primary Completion (Actual)

November 1, 2018

Study Completion (Actual)

November 1, 2018

Study Registration Dates

First Submitted

July 17, 2015

First Submitted That Met QC Criteria

July 30, 2015

First Posted (Estimate)

July 31, 2015

Study Record Updates

Last Update Posted (Actual)

May 1, 2019

Last Update Submitted That Met QC Criteria

April 29, 2019

Last Verified

April 1, 2018

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SUS2015NIBO01

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on same day discharge

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe